Human Molecular Genetics, 2002, Vol. 11, No. 21 2645-2655
© 2002 Oxford University Press
Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology
1Department of Pediatrics and UCLA Duchenne Muscular Dystrophy Research Center, University of California, Los Angeles, CA 90095-1606, USA and 2Department of Pharmacology, Medical College of Ohio, Toledo, OH 43614-5804, USA
Received June 17, 2002; Accepted July 29, 2002
Reduced sarcolemmal integrity in dystrophin-deficient muscles of mdx mice and Duchenne muscular dystrophy (DMD) patients has been reported to result in altered calcium homeostasis. Previous studies have shown a correlative relationship between calcium-dependent protease (calpain) activity in dystrophic muscle and muscle necrosis, but have not tested whether calpain activation precedes cell death or is a consequence of it. To test a causal relationship between calpain activation and muscle cell death in dystrophin deficiency, mdx mice were generated that overexpress a calpastatin transgene in muscle. Calpastatin (CS) is a specific, endogenous inhibitor of m- and µ-calpains that does not inhibit calpain 3 (p94). CS overexpression on a C57/BL 10 background produced no phenotype. Transgenic (Tg) mice crossed with mdx mice were tested for pathological indicators of necrosis, regeneration and membrane damage. Two lines of mice were examined, with different levels of CS overexpression. Both lines of Tg/mdx mice showed reductions in muscle necrosis at 4 weeks of age. These mice had fewer as well as smaller lesions. In addition, one line of mice had significantly less regeneration, indicating a reduction in previous necrosis. The extent of improvement correlated with the level of CS protein expression. Membrane damage, as assessed by procion orange and creatine kinase assays, was unchanged, supporting the idea that calpains act downstream of the primary muscle defect. These data suggest that calpains play an active role in necrotic processes in dystrophic muscle and that inhibition of calpains might provide a good therapeutic option for treatment of DMD.
* To whom correspondence should be addressed at: Duchenne Muscular Dystrophy Research Center, University of California, Los Angeles, 621 Young Drive South, Los Angeles, CA 90095-1606, USA. Tel: +1 3107945225; Fax: +1 3108258489; Email: mspencer{at}mednet.ucla.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Hayashi, Y. Ono, N. Doi, F. Kitamura, M. Tagami, R. Mineki, T. Arai, H. Taguchi, M. Yanagida, S. Hirner, et al. Multiple Molecular Interactions Implicate the Connectin/Titin N2A Region as a Modulating Scaffold for p94/Calpain 3 Activity in Skeletal Muscle J. Biol. Chem., May 23, 2008; 283(21): 14801 - 14814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Stiber, Z.-S. Zhang, J. Burch, J. P. Eu, S. Zhang, G. A. Truskey, M. Seth, N. Yamaguchi, G. Meissner, R. Shah, et al. Mice Lacking Homer 1 Exhibit a Skeletal Myopathy Characterized by Abnormal Transient Receptor Potential Channel Activity Mol. Cell. Biol., April 15, 2008; 28(8): 2637 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, M. C. Liu, and K. K. W. Wang Calpain in the CNS: From Synaptic Function to Neurotoxicity Sci. Signal., April 8, 2008; 1(14): re1 - re1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Claflin and S. V. Brooks Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy Am J Physiol Cell Physiol, February 1, 2008; 294(2): C651 - C658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Skura, E. G. Fowler, G. T. Wetzel, M. Graves, and M. J. Spencer Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy Neurology, January 8, 2008; 70(2): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gailly, F. De Backer, M. Van Schoor, and J. M. Gillis In situ measurements of calpain activity in isolated muscle fibres from normal and dystrophin-lacking mdx mice J. Physiol., August 1, 2007; 582(3): 1261 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Xu, K. Chandrasekharan, J. H. Yoon, M. Camboni, and P. T. Martin Overexpression of the Cytotoxic T Cell (CT) Carbohydrate Inhibits Muscular Dystrophy in the dyW Mouse Model of Congenital Muscular Dystrophy 1A Am. J. Pathol., July 1, 2007; 171(1): 181 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pescatori, A. Broccolini, C. Minetti, E. Bertini, C. Bruno, A. D'amico, C. Bernardini, M. Mirabella, G. Silvestri, V. Giglio, et al. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression FASEB J, April 1, 2007; 21(4): 1210 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Peter, G. Miller, and R. H. Crosbie Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice J. Cell Sci., March 15, 2007; 120(6): 996 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Murphy, E. Verburg, and G. D. Lamb Ca2+ activation of diffusible and bound pools of {micro}-calpain in rat skeletal muscle J. Physiol., October 15, 2006; 576(2): 595 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yoshida, A. Yonetani, T. Shirasaki, and K. Wada Dietary NaCl supplementation prevents muscle necrosis in a mouse model of Duchenne muscular dystrophy Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R449 - R455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. -W. Chen, K. Nagaraju, M. Bakay, O. McIntyre, R. Rawat, R. Shi, and E. P. Hoffman Early onset of inflammation and later involvement of TGF{beta} in Duchenne muscular dystrophy Neurology, September 27, 2005; 65(6): 826 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G Allen, N. P Whitehead, and E. W Yeung Mechanisms of stretch-induced muscle damage in normal and dystrophic muscle: role of ionic changes J. Physiol., September 15, 2005; 567(3): 723 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kramerova, E. Kudryashova, G. Venkatraman, and M. J. Spencer Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway Hum. Mol. Genet., August 1, 2005; 14(15): 2125 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Burkin, G. Q. Wallace, D. J. Milner, E. J. Chaney, J. A. Mulligan, and S. J. Kaufman Transgenic Expression of {alpha}7{beta}1 Integrin Maintains Muscle Integrity, Increases Regenerative Capacity, Promotes Hypertrophy, and Reduces Cardiomyopathy in Dystrophic Mice Am. J. Pathol., January 1, 2005; 166(1): 253 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kramerova, E. Kudryashova, J.G. Tidball, and M. J. Spencer Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro Hum. Mol. Genet., July 1, 2004; 13(13): 1373 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. GROUNDS and J. TORRISI Anti-TNF{alpha} (Remicade(R)) therapy protects dystrophic skeletal muscle from necrosis FASEB J, April 1, 2004; 18(6): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Fowler, M. C. Graves, G. T. Wetzel, and M. J. Spencer Pilot trial of albuterol in Duchenne and Becker muscular dystrophy Neurology, March 23, 2004; 62(6): 1006 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Kent, M. J. Spencer, and M. Koohmaraie Postmortem proteolysis is reduced in transgenic mice overexpressing calpastatin J Anim Sci, March 1, 2004; 82(3): 794 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoyte, V. Jayasinha, B. Xia, and P. T. Martin Transgenic Overexpression of Dystroglycan Does Not Inhibit Muscular Dystrophy in mdx Mice Am. J. Pathol., February 1, 2004; 164(2): 711 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. ENGVALL and U. M. WEWER The new frontier in muscular dystrophy research: booster genes FASEB J, September 1, 2003; 17(12): 1579 - 1584. [Abstract] [Full Text] [PDF]
|
|